Genetic disorders associated with neoplasms, not elsewhere classified (QA1) ICD-10-CM
The QA1 code range covers genetic disorders associated with neoplasms, not elsewhere classified with 8 ICD-10-CM diagnosis codes. 5 of them are billable and valid for claim submission in fiscal year 2027, and the category headers group them but cannot themselves be billed.
Code Also
A "code also" note instructs that two codes may be required to fully describe a condition, but this note does not provide sequencing direction.
- , if applicable, any associated conditions, such as:
- genetic susceptibility to malignant neoplasm by site Z15.0
- malignant neoplasms C00.0 C96.9
- personal history of malignant neoplasm Z85
Type 2 Excludes
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
- multiple endocrine neoplasia [MEN] syndromes E31.2
Codes in the QA1 Range 8 codes · 5 billable
- QA1 Genetic disorders associated with neoplasms, not elsewhere classifiedNon-billable
- QA1.7 Inherited neoplasm predisposition syndromes involving multiple systems, not elsewhere classifiedNon-billable
- QA1.71 Lynch syndrome New
- QA1.79 Other inherited neoplasm predisposition syndrome of multiple systemsNon-billable
- QA1.790 Familial cancer syndrome with pathogenic BRCA1 mutation New
- QA1.791 Familial cancer syndrome with pathogenic BRCA2 mutation New
- QA1.792 Li Fraumeni syndrome New
- QA1.798 Other inherited neoplasm predisposition syndrome of multiple systems New
Clinical Terms in This Code Range
Definitions from the National Library of Medicine for conditions coded in the QA1 range.
Li-Fraumeni Syndrome
Rare autosomal dominant syndrome characterized by mesenchymal and epithelial neoplasms at multiple sites. MUTATION of the p53 tumor suppressor gene, a component of the DNA DAMAGE response pathway, apparently predisposes family members who inherit it to develop certain cancers. The spectrum of cancers in the syndrome was shown to include, in addition to BREAST CANCER and soft tissue sarcomas (SARCOMA); BRAIN TUMORS; OSTEOSARCOMA; LEUKEMIA; and ADRENOCORTICAL CARCINOMA.
Lynch Syndrome
An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.
About the QA1 Code Range
These genetic disorders are associated with neoplasms, or tumors. The listed subdivisions focus on inherited syndromes involving multiple body systems that predispose a person to tumors.
QA1.7 separates Lynch syndrome from other inherited syndromes. Those other syndromes split into familial cancer syndromes with a pathogenic BRCA1 or BRCA2 mutation, Li Fraumeni syndrome, and other inherited syndromes involving multiple systems.
FY 2027 changes: The FY 2027 ICD-10-CM update, effective October 1, 2026, added QA1.71, QA1.790, QA1.791, QA1.792 and QA1.798.
Questions About This Page
How many billable codes are in the QA1 range?
Of the 8 codes in this range, 5 are billable and valid for claim submission from October 1, 2026 through September 30, 2027. Category header codes group them but cannot be reported on claims.
What does the QA1 range classify?
The range classifies genetic disorders associated with neoplasms, not elsewhere classified. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2027 ICD-10-CM Tabular List and order file, effective October 1, 2026 through September 30, 2027.
